Modern Radiation Further Improves Survival in Non-Small Cell Lung Cancer: An Analysis of 288,670 Patients

Abstract

Background: Radiation therapy plays an increasingly important role in the treatment of patients with non-small-cell lung cancer (NSCLC). The purpose of the present study is to assess the survival outcomes of radiotherapy treatment compared to other treatment modalities and to determine the potential role of advanced technologies in radiotherapy on improving survival.Methods: We used cancer incidence and survival data from the Surveillance, Epidemiology, and End Results database linked to U.S. Census data to compare survival outcomes of 288,670 patients with stage I-IV NSCLC treated between 1999 and 2008. The primary endpoint was overall survival.Results: Among the 288,670 patients diagnosed with stage I-IV NSCLC, 92,374 (32%) patients received radiotherapy—almost double the number receiving surgery (51,961, 18%). Compared to other treatment groups and across all stages of NSCLC, patients treated with radiotherapy showed greater median and overall survival than patients without radiation treatment (p < 0.0001). Radiotherapy had effectively improved overall survival regardless of age, gender, and histological categorization. Radiotherapy treatment received during the recent time period 2004 - 2008 is correlated with enhanced survival compared to the earlier time period 1999 - 2003.Conclusion: Radiation therapy was correlated with increased overall survival for all patients with primary NSCLC across stages. Combined surgery and radiotherapy treatment also correlates with improved survival, signaling the value of bimodal or multimodal treatments. Population-based increases in overall survival were seen in the recent time period, suggesting the potential role of advanced radiotherapeutic technologies in enhancing survival outcomes for lung cancer patients.

Spatial heterogeneity of radiolabeled choline positron emission tomography in tumors of patients with non-small cell lung cancer: first-in-patient evaluation of [18F]fluoromethyl-(1,2-2H4)-choline

“…Radiotherapy, alone or in combination with systemic therapies are the mainstay of treatment in patients diagnosed with stage I-IV NSCLC, and with advances in radiotherapy planning and delivery, a remarkable improvement in local tumor control has been seen 10 , 11 . It is hypothesized that imaging approaches for detecting the multiple factors that influence radioresistance would make further impact.…”

2D Nanomaterial, Ti3C2 MXene-Based Sensor to Guide Lung Cancer Therapy and Management

“…To increase the survival rate, major advances in lung cancer control or prevention can be facilitated by early detection and effective anti-cancer therapy. In recent years, a variety of therapeutic and adjuvant methods and nutritional approaches have been developed for lung cancer treatment such as chemotherapy, targeted therapy [8,9], cyclooxygenase (COX)-2 inhibition [10], and omega-3 fatty acid dietary manipulation [11,12].…”

Identification of potential descriptors of water-soluble fullerene derivatives responsible for antitumor effects on lung cancer cells via QSAR analysis

“…The survival rate of patients with lung cancer is still pretty low despite the advances in drug therapy and diagnosis [5] , [6] . The common treatment strategies of lung cancer include chemotherapy [7] , radiation therapy [8] , systemic therapy [9] , targeted therapy [10] , and immunotherapy [11] . For the current cancer treatments, there is no effective therapeutic strategy for most patients with metastatic lung cancer.…”